Article Text

other Versions

Download PDFPDF
Ovarian sex cord-stromal tumors: an update on clinical features, molecular changes, and management
  1. Rehab Al Harbi1,
  2. Iain A McNeish2 and
  3. Mona El-Bahrawy1,3
  1. 1Department of Metabolism, Digestion, and Reproduction, Imperial College London, London, UK
  2. 2Department of Surgery and Cancer, Imperial College London, London, UK
  3. 3Department of Pathology, Faculty of Medicine, University of Alexandria, Alexandria, Egypt
  1. Correspondence to Professor Mona El-Bahrawy, Metabolism, Digestion, and Reproduction, Imperial College London Faculty of Medicine, London, W12 0NN, UK; m.elbahrawy{at}


Sex cord stromal-tumors are rare tumors of the ovary that include numerous tumor subtypes of variable histological features and biological behavior. Surgery is the main therapeutic modality for the management of these tumors, while chemotherapy and hormonal therapy may be used in some patients with progressive and recurrent tumors. Several studies investigated molecular changes in the different tumor types. Understanding molecular changes underlying the development and progression of sex cord-stromal tumors provides valuable information for diagnostic and prognostic biomarkers and potential therapeutic targets for these tumors. In this review, we provide an update on the clinical presentation, molecular changes, and management of sex cord-stromal tumors.

  • ovarian cancer
  • sex cord-gonadal stromal tumors

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors RAH: preparation of the manuscript. IAM: revision of the manuscript. ME-B: concept, design, and revision of the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Linked Articles